Literature DB >> 9554387

Renal deterioration in myelodysplastic children: urodynamic evaluation and clinical correlates.

E A Kurzrock1, S Polse.   

Abstract

PURPOSE: We determined which factors portend a higher risk of renal deterioration in the myelodysplastic child, and evaluated the sensitivity and predictive value.
MATERIALS AND METHODS: We retrospectively reviewed the medical history, imaging studies and urodynamics of 90 children with spinal dysraphism. Median patient age at initial evaluation was 3 months and average followup ranged between 2 and 25 years (average 11). We evaluated the relation of urodynamic parameters and sex to upper tract changes and the resolution of these changes.
RESULTS: Statistically significant relationships were identified between the urodynamic parameters of leak point pressure, compliance and detrusor-sphincter dyssynergia, and renal deterioration but not with resolution of deterioration. Boys and girls did not demonstrate a significant difference among urodynamic parameters. Female patients had a higher incidence of reflux and parenchymal loss.
CONCLUSIONS: With knowledge of the inherent sensitivity, specificity and predictive value of urodynamic parameters, selective use of urodynamics will assist in identifying patients at risk of renal deterioration. Female patients with reflux are at greatest risk of parenchymal loss. We advocate early institution of intermittent catheterization in patients identified as high risk for deterioration by urodynamics.

Entities:  

Mesh:

Year:  1998        PMID: 9554387     DOI: 10.1097/00005392-199805000-00084

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

Review 1.  How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?

Authors:  Maximilien Baron; Philippe Grise; Jean-Nicolas Cornu
Journal:  World J Nephrol       Date:  2016-03-06

2.  Urinary tract infections in children with myelodysplasia in whom clean intermittent catheterization was administered.

Authors:  Zuhal Albayrak Yıldız; Cengiz Candan; Mustafa Arga; Pınar Turhan; Pınar İşgüven; Müferet Ergüven
Journal:  Turk Pediatri Ars       Date:  2014-03-01

3.  Inosculation of blood vessels allows early perfusion and vitality of bladder grafts--implications for bioengineered bladder wall.

Authors:  Stephanie L Osborn; Michelle So; Shannon Hambro; Jan A Nolta; Eric A Kurzrock
Journal:  Tissue Eng Part A       Date:  2015-04-22       Impact factor: 3.845

4.  Renal cortical deterioration in children with spinal dysraphism: analysis of risk factors.

Authors:  Sean M DeLair; Jonathan Eandi; Marina J White; Thuan Nguyen; Anthony R Stone; Eric A Kurzrock
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

Review 5.  Intravesical oxybutynin in the pediatric neurogenic bladder.

Authors:  John Lazarus
Journal:  Nat Rev Urol       Date:  2009-11-10       Impact factor: 14.432

6.  Vesico-ureteral reflux in women with idiopathic high-pressure detrusor overactivity: prevalence, bladder function, and effect on the upper urinary tract.

Authors:  Adam Gafni-Kane; Peter K Sand
Journal:  Int Urogynecol J       Date:  2014-05-07       Impact factor: 2.894

7.  The predictive factors of hydronephrosis in patients with spina bifida: reports from China.

Authors:  Yan Ma; Bing Li; Longwang Wang; Xiaomin Han
Journal:  Int Urol Nephrol       Date:  2013-03-13       Impact factor: 2.370

8.  Pediatric enterocystoplasty: long-term complications and controversies.

Authors:  Eric A Kurzrock
Journal:  World J Urol       Date:  2008-10-10       Impact factor: 4.226

9.  Application of data mining techniques to explore predictors of upper urinary tract damage in patients with neurogenic bladder.

Authors:  H Fang; B Lu; X Wang; L Zheng; K Sun; W Cai
Journal:  Braz J Med Biol Res       Date:  2017-08-17       Impact factor: 2.590

Review 10.  The neurogenic bladder: medical treatment.

Authors:  Carla Verpoorten; Gunnar M Buyse
Journal:  Pediatr Nephrol       Date:  2007-12-19       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.